Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures. Join the conversation, on Tuesday 28th January @ 10 am ...

Sanofi S.A. Part Cert 0.06% €8.19M ...

But we'll be back tomorrow with more updates on the war in Ukraine. Here are the key lines from today: Outgoing US defence secretary Lloyd Austin announced a $500m (£407m) aid package for Ukraine ...